Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Name: Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial
Creator: Linda Stein Gold
Published: 2022-10-14T18:34:20.648Z
Keywords: Clinical Trial, Scalp, Psoriasis, Quality of Life, Pruritus

Stein Gold, Linda; Papp, Kim; Pariser, David; Bhatia, Neal; Sofen, Howard; Albrecht, Lorne; gooderham, melinda; Callis Duffin, Kristina; Chen, Mindy; Paris, Maria; Cheng, Sue; Picard, Hernan; Wang, Yao; Green, Lawrence

doi:10.17632/wf4g3yxvzz.1

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Published: 14 October 2022| Version 1 | DOI: 10.17632/wf4g3yxvzz.1

Contributors:

Linda Stein Gold,

, David Pariser,

, Howard Sofen, Lorne Albrecht,

, Kristina Callis Duffin, Mindy Chen, Maria Paris, Sue Cheng, Hernan Picard, Yao Wang,

Description

Mendeley Supplemental Figures for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial. J Am Acad Dermatol. 2022.

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Description

Files

Categories

Licence